A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies
Latest Information Update: 04 Oct 2024
At a glance
- Drugs LOXO-338 (Primary) ; Pirtobrutinib (Primary)
- Indications B-cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Richter's syndrome; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Eli Lilly and Company
- 28 May 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 15 Jun 2023 Results (As of 18 October 2022,n= 22 ), presented at the 28th Congress of the European Haematology Association
- 30 May 2023 Planned End Date changed from 1 Apr 2024 to 1 Dec 2023.